Should I buy Revvity (RVTY) stock or is it too late?

Revvity · Health Care · price $155

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Barclays — 60% of its targets hit on this sector (645 calls tested). It aims for $160 (+3.2 %), call made on October 8, 2026, maturing on October 8, 2027 (6 d ago).

The 2 reliable analysts $143-7.8 %

The 6 other firms $130-16 %

How to read it: the 2 reliable firms are not filtered by optimism — 1 aim above the price, 1 below, hence their $143 median. “The 6 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Revvity

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Raymond James	44 %	+3.5 %	9	$115 -26%
Barclays	20 %	+2.5 %	5	$160 +3%
Baird	20 %	-8.8 %	5	$125 -19%

In short — Should you invest in Revvity? Is it too late, still worth it? Analysts are fairly positive (56% buy, median target $126, i.e. -19%). But the valuation is stretched (P/E ~75), it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Few solid positives from analysts right now: of 9 ratings, only 5 buys, and the median price target ($126) is -19% below the price ($155). Caution prevails.

⚠️ Reasons to hesitate

Even the most reliable firm on RVTY, Evercore ISI Group (100% hit rate, 3 scored calls), only targets $126 (call made on August 5, 2026, maturing on August 5, 2027) (-19%) in its most recent call, and $118 (call made on February 3, 2026, maturing on February 3, 2027) (-24%) in the one coming due soonest. The stock may already have run past its target.
The consensus is not unanimous: of 9 ratings, 4 are neutral.
Limited upside: the median target is only -19% from the current price.
High valuation (P/E ~75): strong growth is already "priced in", leaving little room for error.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
Negligible dividend (0.3% yield): your return depends mostly on price appreciation.

The analyst consensus on RVTY

Median target $126 (-19%) · 9 ratings · Buy consensus

Strong Buy00%

Buy556%

Hold444%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Revvity now?

We won't decide for you. The facts: 56% of analysts rate it a buy, median target $126 (-19%), and Evercore ISI Group (most reliable on RVTY, 100%) targets $126. Weigh that against valuation (P/E ~75). This is not personalized advice.

Is it too late to invest in Revvity?

The stated upside is small: the median target ($126) sits just -19% from the price ($155) (most reliable on RVTY: Evercore ISI Group, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Revvity still worth investing in?

It depends on the gap between the price ($155) and its estimated value: analysts target $126 on median (-19%), with 56% buys (most reliable on RVTY: Evercore ISI Group, 100%). Cross-check with their real reliability on RVTY and the cautions above. Information, not advice.

What's the main risk in buying RVTY?

Even the most reliable firm on RVTY, Evercore ISI Group (100% hit rate, 3 scored calls), only targets $126 (call made on August 5, 2026, maturing on August 5, 2027) (-19%) in its most recent call, and $118 (call made on February 3, 2026, maturing on February 3, 2027) (-24%) in the one coming due soonest. The stock may already have run past its target.

→ Go deeper: the full Revvity profile (consensus, analyst reliability, price target, performance).